BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Gopal R, Selvarasu K, Pandian PP, Ganesan K. Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression. Cell Oncol (Dordr) 2017;40:219-33. [PMID: 28390038 DOI: 10.1007/s13402-017-0321-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
2 Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol 2014; 20(46): 17483-17490 [PMID: 25516662 DOI: 10.3748/wjg.v20.i46.17483] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
3 Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN, Xu GL. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur J Surg Oncol 2013;39:1129-35. [PMID: 23916473 DOI: 10.1016/j.ejso.2013.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
4 Gozzi GJ, Pires Ado R, Valdameri G, Rocha ME, Martinez GR, Noleto GR, Acco A, Alves de Souza CE, Echevarria A, Moretto Dos Reis C, Di Pietro A, Suter Correia Cadena SM. Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2). PLoS One 2015;10:e0130046. [PMID: 26083249 DOI: 10.1371/journal.pone.0130046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
5 Nguyen CB, Kotturi H, Waris G, Mohammed A, Chandrakesan P, May R, Sureban S, Weygant N, Qu D, Rao CV, Dhanasekaran DN, Bronze MS, Houchen CW, Ali N. (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res 2016;76:4887-96. [PMID: 27287718 DOI: 10.1158/0008-5472.CAN-15-2722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Li J, Ling W, Chen S, Yang L, Ma L, Lu Q, Luo Y. Can Risk Stratification Based on Ultrasound Elastography of Background Liver Assist CEUS LI-RADS in the Diagnosis of HCC? Front Oncol 2021;11:662680. [PMID: 33996586 DOI: 10.3389/fonc.2021.662680] [Reference Citation Analysis]
7 Nie G, Peng D, Li B, Lu J, Xiong X. Diagnostic Accuracy of Circular RNAs in Different Types of Samples for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:794105. [PMID: 34992634 DOI: 10.3389/fgene.2021.794105] [Reference Citation Analysis]
8 Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235-244. [PMID: 25101233 DOI: 10.1007/s11901-014-0238-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
9 Zheng J, Li C, Wu X, Yang Y, Hao M, Sheng S, Sun Y, Zhang H, Long J, Hu C. Astrocyte elevated gene-1 is a novel biomarker of epithelial-mesenchymal transition and progression of hepatocellular carcinoma in two China regions. Tumour Biol. 2014;35:2265-2269. [PMID: 24136747 DOI: 10.1007/s13277-013-1300-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
10 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54. [PMID: 25153274 DOI: 10.1148/radiol.14132361] [Cited by in Crossref: 236] [Cited by in F6Publishing: 202] [Article Influence: 29.5] [Reference Citation Analysis]
11 Zheng Y, Yang F, Fu L, Liu K. The mechanism of miR-143 inducing apoptosis of liver carcinoma cells through regulation of the NF-κB pathway. Oncol Lett 2018;15:9567-71. [PMID: 29844837 DOI: 10.3892/ol.2018.8486] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Liu J, Pei Y, Zhang Y, Wu Y, Liu F, Gu S. Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features. Abdom Radiol (NY) 2021;46:3748-57. [PMID: 33386449 DOI: 10.1007/s00261-020-02891-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 El-Zefzafy W, Eltokhy H, Mohamed NA, Abu-Zahab Z. Significance of Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma in Chronic Hepatitis C Infected Egyptian Patients. Open Access Maced J Med Sci 2015;3:117-23. [PMID: 27275207 DOI: 10.3889/oamjms.2015.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
14 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 339] [Article Influence: 45.5] [Reference Citation Analysis]
15 Yu Y, Zhao Y, Zhou G, Wang X. Therapeutic Efficacy of Delta-Like Ligand 4 Gene Vaccine Overexpression on Liver Cancer in Mice. Technol Cancer Res Treat 2020;19:1533033820942205. [PMID: 33191858 DOI: 10.1177/1533033820942205] [Reference Citation Analysis]
16 Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014;5:221-230. [PMID: 24665346 DOI: 10.7150/jca.7691] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
17 Fu J, Zhang JY, Wang FS. Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. Hepatol Int 2014;8:1-3. [PMID: 26202399 DOI: 10.1007/s12072-013-9493-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Jia Y, Chen Y, Liu J. Prognosis-Predictive Signature and Nomogram Based on Autophagy-Related Long Non-coding RNAs for Hepatocellular Carcinoma. Front Genet 2020;11:608668. [PMID: 33424932 DOI: 10.3389/fgene.2020.608668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
19 Zhu XL, Wang YL, Chen JP, Duan LL, Cong PF, Qu YC, Li-Ling J, Zhang MX. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. Tumour Biol. 2014;35:1627-1635. [PMID: 24078466 DOI: 10.1007/s13277-013-1224-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
20 Ji M, Liu Z, Chang ET, Yu X, Wu B, Deng L, Feng Q, Wei K, Liang X, Lian S, Quan W, Wang P, Du Y, Liang Z, Xia S, Lin H, Li F, Cheng W, Chen W, Yuan Y, Ye W. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. Sci Rep 2018;8:12787. [PMID: 30143694 DOI: 10.1038/s41598-018-31119-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
21 Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E. In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol Ther 2014;22:634-44. [PMID: 24445938 DOI: 10.1038/mt.2013.277] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
22 Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, Hosseinzadeh F, Iranikhah A, Shirian S. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int 2018;18:133. [PMID: 30214375 DOI: 10.1186/s12935-018-0624-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zheng W, Sai W, Yao M, Gu H, Yao Y, Qian Q, Yao D. Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. Tumour Biol. 2015;36:3995-4003. [PMID: 25600802 DOI: 10.1007/s13277-015] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Rabei R, Vakil P, King B, Lokken RP, Heller M, Fidelman N, Kohi M. Frailty as a Predictor of Complications and Transplant-Free Survival after Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Clinical Interventional Radiology ISVIR. [DOI: 10.1055/s-0042-1745775] [Reference Citation Analysis]
25 Willatt J, Hannawa KK, Ruma JA, Frankel TL, Owen D, Barman PM. Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. World J Hepatol 2015; 7(2): 235-244 [PMID: 25729478 DOI: 10.4254/wjh.v7.i2.235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
26 Negroni L, Taouji S, Arma D, Pallares-Lupon N, Leong K, Beausang LA, Latterich M, Bossé R, Balabaud C, Schmitter JM, Bioulac-Sage P, Zucman-Rossi J, Rosenbaum J, Chevet E. Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers. Mol Cell Proteomics 2014;13:3473-83. [PMID: 25225353 DOI: 10.1074/mcp.M114.043174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
27 Huang Y, Zeng J, Liu T, Lin X, Guo P, Zeng J, Zhou W, Liu J. Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4559-67. [PMID: 32547086 DOI: 10.2147/OTT.S236475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Li Z, Sun YM, Wu FX, Yang LQ, Lu ZJ, Yu WF. Controlled low central venous pressure reduces blood loss and transfusion requirements in hepatectomy. World J Gastroenterol 2014; 20(1): 303-309 [PMID: 24415886 DOI: 10.3748/wjg.v20.i1.303] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
29 Lee J, Zhou W, Na M, Oh S. Cytotoxic Activity of Aplykurodin A Isolated From Aplysia kurodai against AXIN1-Mutated Hepatocellular Carcinoma Cells by Promoting Oncogenic β-Catenin Degradation. Mar Drugs 2020;18:E210. [PMID: 32294900 DOI: 10.3390/md18040210] [Reference Citation Analysis]
30 Braat MN, Samim M, van den Bosch MA, Lam MG. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging 2016;4:283-95. [PMID: 27512689 DOI: 10.1007/s40336-016-0172-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
31 Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol 2016;7:82-9. [PMID: 28840911 DOI: 10.1136/flgastro-2015-100617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
33 Wong VC, Wong MI, Lam CT, Lung ML, Lam KO, Lee VH. Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis. J Cancer 2021;12:4585-94. [PMID: 34149922 DOI: 10.7150/jca.59933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Nguyen CB, Houchen CW, Ali N. APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 2017;242:242-9. [PMID: 27694285 DOI: 10.1177/1535370216672746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
36 Abara WE, Spradling P, Zhong Y, Moorman A, Teshale EH, Rupp L, Gordon SC, Schmidt M, Boscarino JA, Daida YG, Holmberg SD; CHeCS Investigators. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer 2020;51:461-8. [PMID: 31124041 DOI: 10.1007/s12029-019-00255-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
38 Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol 2014;10:721. [PMID: 24646661 DOI: 10.1002/msb.145122] [Cited by in Crossref: 216] [Cited by in F6Publishing: 174] [Article Influence: 27.0] [Reference Citation Analysis]
39 Yokoo T, Patel AD, Lev-Cohain N, Singal AG, Yopp AC, Pedrosa I. Extrahepatic metastasis risk of hepatocellular carcinoma based on α-fetoprotein and tumor staging parameters at cross-sectional imaging. Cancer Manag Res 2017;9:503-11. [PMID: 29081671 DOI: 10.2147/CMAR.S147097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
40 Barman PM, Sharma P, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci. 2014;59:2821-2825. [PMID: 24973040 DOI: 10.1007/s10620-014-3247-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
41 Negussie AH, Dreher MR, Johnson CG, Tang Y, Lewis AL, Storm G, Sharma KV, Wood BJ. Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization. J Mater Sci Mater Med 2015;26:198. [PMID: 26105830 DOI: 10.1007/s10856-015-5530-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
42 Demir M, Nigemeier J, Kütting F, Bowe A, Schramm C, Hoffmann V, Waldschmidt D, Goeser T, Steffen HM. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection 2015;43:153-62. [PMID: 25701223 DOI: 10.1007/s15010-015-0751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
44 de Oliveira RM, Ornelas Ricart CA, Araujo Martins AM. Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma. Front Oncol. 2017;7:328. [PMID: 29379771 DOI: 10.3389/fonc.2017.00328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
45 Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128:90.e1-90.e7. [PMID: 25116425 DOI: 10.1016/j.amjmed.2014.07.027] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]